

# CURE ID

July Newsletter

Q&A Videos



In a further effort to extend our reach and visibility, a series of interviews was recorded at the CDRC Annual Meeting from key stakeholders within the Collaboratory. Check out Shira Strongin, MS, ORISE Fellow, FDA Office of Medical Policy on CURE ID and CURE Drug Repurposing Collaboratory (CDRC) member. Check it out (and feel free to share it on social) [here](#).

## Publication Announcement: Fosfomycin for Non-Urinary Tract Infections: a systematic review

### Fosfomycin for Non-Urinary Tract Infections: a systematic review

shreya Das Adhikari<sup>1</sup>, Souvik Chaudhuri<sup>1</sup>, Carl Boodman<sup>2</sup>, Mukund Gupta<sup>3</sup>, Marco Schito<sup>4</sup>, Heather Stone<sup>5</sup>, Nitin Gupta<sup>6</sup>

<sup>1</sup>Department of Anesthesiology, All India Institute of Medical Sciences, Faridkot, Haryana, India; <sup>2</sup>Department of Critical Care, Kasturba Medical College and Hospital, Manipal, Manipal Academy of Higher Education, Bidar Nagar, Karnataka, India; <sup>3</sup>Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Manitoba, Canada; <sup>4</sup>Department of Community Medicine and Family Medicine, All India Institute of Medical Sciences, Jodhpur, India; <sup>5</sup>CURE Drug Repurposing Collaboratory (CDRC), Critical Path Institute, Tucson, AZ, United States of America; <sup>6</sup>United States Food & Drug Administration, Silver Spring, MD 20993, United States of America; <sup>7</sup>Department of Infectious Diseases, Kasturba Medical College and Hospital, Manipal, Manipal Academy of Higher Education, Bidar Nagar, Karnataka, India

Article received 11 January 2023, accepted 12 April 2023

#### SUMMARY

**Introduction:** Although fosfomycin is currently approved for treating urinary tract infections, it is increasingly being used as salvage therapy for various infectious syndromes outside the urinary tract. This systematic review evaluates clinical and microbiological cure rates in patients with bacterial infections not restricted to the urinary tract where fosfomycin was used as first-line, adjunctive, and de-escalation therapy. The design, risks, and duration of fosfomycin therapy along with the results of adjunctive antimicrobial agents were noted. The final database captured seven studies, including biological control, fosfomycin, and fosfomycin plus other antimicrobials. A total of 947 articles, not including duplicates, were selected for the title and abstract screening. After title and abstract screening, 102 articles were kept for full-text screening. Of the 102 articles, 23 studies (no-227 patients) were kept in the final analysis. Of these 227 pa-

tients, 361 (27%) received fosfomycin as monotherapy, and the remaining 166 (73%) received fosfomycin in combination with other antimicrobials. Most of the patients received intravenous fosfomycin (no-186, 81%). Fosfomycin cure rates were 75% and 84%, respectively.

**Conclusion:** Fosfomycin has moderate clinical success in patients with non-urinary tract infections, especially when used with other antimicrobials. Due to the paucity of evidence, fosfomycin use should be limited to situations where no alternatives are supported by better clinical evidence.

**Keywords:** fosfomycin, Central Nervous System, fosfomycin.

Fosfomycin for Non-Urinary Tract Infections: a systematic review. Although Fosfomycin is currently approved for treating urinary tract infections, it is increasingly being used as salvage therapy for various infectious syndromes outside the urinary tract.

Authors: shreya Das Adhikari, Souvik Chaudhuri, Carl Boodman, Mukund Gupta, Marco Schito, Heather Stone, Nitin Gupta

## CURE ID Updates

1. EHR data visualization
2. Report forms updates (Sarcoma CRF and Long Covid CRF)
3. New UI design for account section
4. Filter improvements
5. Bug fixes

## ASCO Recap



Inish O'Doherty, who used to be an executive director at C-Path meets with Marco Schito (pictured right). The Top is Marco Schito, and Chandler Birch meeting with the Osteosarcoma Group, MIB (Mary Katherine Clark, and Mac Tichenor) who are leaders for the group and were very receptive to CDRC sarcoma projects, however timing dictates that they wait for the moment. The bottom is an international group of collaborating physicians and clinical trialists whom are engaged with CDRC on a global clinical master protocol for rare sarcomas.

Osteosarcoma Drug Repurposing clip: <https://www.cbsnews.com/pittsburgh/video/pittsburgh-and-cleveland-doctors-join-forces-to-fight-bone-cancer/>

## CeBIL recap



Marco Schito had the opportunity to travel to Europe for multiple conferences. One of them was the CeBIL symposium: Sustainable health innovation, grand challenges & the law at the University of Copenhagen. Pictures is a panel Marco sat on which included John Liddicoat (Kings College London), Kathy Liddell (University of Cambridge), Matt Fisher (University College London), and the organizer Timo Minssen (University of Copenhagen).

## Events

### 8th International RASopathies Symposium: Expanding Research and Care Practice through Global Collaboration and Advocacy

July 21-23, 2023, Denver Marriott Tech Center, Denver, Colorado

The RASopathies Network's patient/family advocate-driven model gathers diverse stakeholders to discuss cutting edge science, current gaps in knowledge, and future milestones, toward improving health and bringing treatments to people with RASopathies. We distinguish this symposium from others by being highly multidisciplinary, science-focused and inclusive of advocates and families, while being distinct from meetings that convene to discuss oncology or RAS-targeted drug discovery. Marco Schito will be in attendance. For more information, click [here](#).

### Critical Care Datathon

August 5th and 6th, New York

The Society of Critical Care Medicine's (SCCM) Datathon is a collaborative event connecting clinicians with data scientists to develop pragmatic data-driven models applicable to the care of critically ill patients using de-identified critical care electronic health record datasets.

The Datathon demonstrates the multiprofessional approach required to successfully analyze large datasets. It combines medical science and data science techniques to address real-world problems using existing datasets. The Datathon is part of Discovery, the Critical Care Research Network, and is designed to synthesize critical problem solving and data analytics, promote multiprofessional collaboration, and increase data science knowledge and innovation. The goal is to identify projects that have the potential to lead to publication and improve the care of critically ill patients. Critical care clinicians, researchers, and data scientists are encouraged to participate. Clinicians do not need to have existing data science knowledge. [Register Here](#)

## Trending Articles

[Fungal Meningitis Outbreak Associated with Procedures Performed under Epidural Anesthesia in Matamoros, Mexico](#)

[Continuous vs Intermittent Meropenem Administration in Critically Ill Patients With Sepsis](#)

[The MERCY Randomized Clinical Trial](#)

[Achieving Impact: Charting the Course to Meet the Challenges Ahead at the 12th International Conference on Typhoid and Other Invasive Salmonellosis](#)

## Awareness Month



## CURE ID/CDRC Social Media Ambassador

### Looking to become a social media ambassador?

CURE ID is looking to recruit individuals interested in help promoting our web-based app. The platform enables healthcare providers to share their real-world experiences treating patients with repurposed drugs. We currently have 20 social media ambassadors and looking to expand.

This is an unpaid position but can win CURE ID/CDRC swag.

This is a competitive opportunity to bring on more followers, tweets, discussion posts, and win some swag!

If interested please reach out to [cbassetti@c-path.org](mailto:cbassetti@c-path.org)



## Be Heard

### Tell Your Drug Repurposing Story in 2023

Our Impact stories share the value and impact C-Path's and CDRC's work brings to patients, patient organizations, drug developers, the academic community, regulators and more. Enjoy and share! [Impact Stories](#) | [Critical Path Institute \(c-path.org\)](#)

Reach out to the Communication and Patient Engagement Manager, Claire Bassetti at [cbassetti@c-path.org](mailto:cbassetti@c-path.org) if interested in sharing your story through an Impact Story.

## Joining the CDRC



The CURE Drug Repurposing Collaboratory (CDRC) is a public-private partnership initiated in June 2020 by C-Path and the U.S. Food and Drug Administration (FDA) in partnership with the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH).

If interested, please feel free to get involved with the CURE Drug Repurposing Collaboratory (CDRC), here: <https://c-path.org/cdrc>

## Collaborators



## Brought to you by



## Visit CURE ID

Visit the CURE ID website for more information. <https://cure.ncats.io>



## Get the CURE ID Mobile App



You received this email because you registered for CURE ID or signed up to receive our monthly newsletter. If you have any questions regarding this communication, please contact us at [curesupport@nih.gov](mailto:curesupport@nih.gov)